James C. Fuscoe Source Confirmed

OverviewAI-generated summary

James C. Fuscoe's research focuses on understanding and mitigating the cardiotoxic effects of chemotherapy, particularly doxorubicin. His work investigates the molecular mechanisms underlying drug-induced heart damage, exploring potential biomarkers for early detection and intervention. Recent publications have examined the role of microRNA-34a-5p as a preclinical biomarker for doxorubicin-induced chronic cardiotoxicity and the delayed-onset subclinical cardiotoxicity in mouse models. Fuscoe has also explored sex-related differential cardiotoxicity induced by doxorubicin, investigating the involvement of the apelin-APJ pathway.

Further research efforts have concentrated on identifying predictive risk factors for myocardial injury in children treated with anthracyclines, as indicated by a pilot study. Fuscoe's scholarship metrics include an h-index of 46, with 163 total publications and over 13,000 citations, designating him as a highly cited researcher. He actively collaborates with researchers at the National Center for Toxicological Research and the University of Arkansas for Medical Sciences, maintaining an active laboratory website to disseminate his findings. His recent activity confirms his ongoing engagement in the field.

Metrics

• h-index: 46
• Publications: 163
• Citations: 13,235